127 related articles for article (PubMed ID: 20979875)
21. Amplification of Her-2/neu gene in Her-2/neu-overexpressing and -nonexpressing breast carcinomas and their synchronous benign, premalignant, and metastatic lesions detected by FISH in archival material.
Xu R; Perle MA; Inghirami G; Chan W; Delgado Y; Feiner H
Mod Pathol; 2002 Feb; 15(2):116-24. PubMed ID: 11850540
[TBL] [Abstract][Full Text] [Related]
22. The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.
Short SM; Yoder BJ; Tarr SM; Prescott NL; Laniauskas S; Coleman KA; Downs-Kelly E; Pettay JD; Choueiri TK; Crowe JP; Tubbs RR; Budd TG; Hicks DG
Breast J; 2007; 13(2):130-9. PubMed ID: 17319853
[TBL] [Abstract][Full Text] [Related]
23. mRNA in situ hybridization (HistoSonda): a new diagnostic tool for HER2-status in breast cancer-a multicentric Spanish study.
Bernet L; Martinez Benaclocha M; Castera C; Cano Muñoz R; Sevilla F; Alba J; de Dios Barranco J; Cordoba A; Garcia-Caballero T; Hardisson D; de Francisco Hernandez JM; Lazaro JM; Polo L; Riu F; Rezola R; Rojo F; Ruiz I; Hernándiz A; de la Cámara de Las Heras JM; Coupe VM
Diagn Mol Pathol; 2012 Jun; 21(2):84-92. PubMed ID: 22555091
[TBL] [Abstract][Full Text] [Related]
24. [Comparative investigations of the determination of the HER-2 status in breast cancer by fluorescence and chromogenic in situ hybridization].
Zavalishina LE; riazantseva AA; Bataeva MV; Andreeva IuIu; Frank GA
Arkh Patol; 2008; 70(3):9-11. PubMed ID: 18727424
[TBL] [Abstract][Full Text] [Related]
25. Strong correlation between results of fluorescent in situ hybridization and immunohistochemistry for the assessment of the ERBB2 (HER-2/neu) gene status in breast carcinoma.
Couturier J; Vincent-Salomon A; Nicolas A; Beuzeboc P; Mouret E; Zafrani B; Sastre-Garau X
Mod Pathol; 2000 Nov; 13(11):1238-43. PubMed ID: 11106082
[TBL] [Abstract][Full Text] [Related]
26. [Evaluation on parallel HER-2 testing using in situ hybridization and immunohistochemistry in breast cancer tissues].
Pan XY; Gao HY; Zhang JL; Fu WT; Liu S
Nan Fang Yi Ke Da Xue Xue Bao; 2009 Nov; 29(11):2225-7. PubMed ID: 19923073
[TBL] [Abstract][Full Text] [Related]
27. Estrogen receptor-negative and human epidermal growth factor receptor 2-negative breast cancer tissue have the highest Ki-67 labeling index and EGFR expression: gene amplification does not contribute to EGFR expression.
Umemura S; Takekoshi S; Suzuki Y; Saitoh Y; Tokuda Y; Osamura RY
Oncol Rep; 2005 Aug; 14(2):337-43. PubMed ID: 16012712
[TBL] [Abstract][Full Text] [Related]
28. Histological tumor grade correlates with HER2/c-erB-2 status in invasive breast cancer: a comparative analysis between immunohistochemical (CB11 clone and Herceptest), FISH and differential PCR procedures.
López-Guerrero JA; Navarro S; Noguera R; Almenar S; Pellin A; Vázquez C; Llombart-Bosch A
Arkh Patol; 2003; 65(1):50-5. PubMed ID: 12669615
[TBL] [Abstract][Full Text] [Related]
29. Detection of Her-2/neu oncogene in breast carcinoma by chromogenic in situ hybridization in cytologic specimens.
Lin F; Shen T; Prichard JW
Diagn Cytopathol; 2005 Dec; 33(6):376-80. PubMed ID: 16299744
[TBL] [Abstract][Full Text] [Related]
30. Concordance of HER2 status assessed on needle core biopsy and surgical specimens of invasive carcinoma of the breast.
Lee AH; Key HP; Bell JA; Hodi Z; Ellis IO
Histopathology; 2012 May; 60(6):880-4. PubMed ID: 22320892
[TBL] [Abstract][Full Text] [Related]
31. Comparison of HER-2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinoma.
Gong Y; Booser DJ; Sneige N
Cancer; 2005 May; 103(9):1763-9. PubMed ID: 15786420
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of HER-2/neu gene amplification by fluorescence in situ hybridization and immunohistochemistry in saudi female breast cancer.
Al-Khattabi H; Kelany A; Buhmeida A; Al-Maghrabi J; Lari S; Chaudhary A; Gari M; Abuzenadah A; Al-Qahtani M
Anticancer Res; 2010 Oct; 30(10):4081-8. PubMed ID: 21036723
[TBL] [Abstract][Full Text] [Related]
33. [HER2 gene amplification assay: is CISH an alternative to FISH?].
Denoux Y; Arnould L; Fiche M; Lannes B; Couturier J; Vincent-Salomon A; Penault-Llorca F; Antoine M; Balaton A; Baranzelli MC; Becette V; Bellocq JP; Bibeau F; Ettore F; Fridman V; Gnassia JP; Jacquemier J; MacGrogan G; Mathieu MC; Migeon C; Rigaud C; Roger P; Sigal-Zafrani B; Simony-Lafontaine J; Trassard M; Treilleux I; Verriele V; Voigt JJ;
Ann Pathol; 2003 Dec; 23(6):617-22. PubMed ID: 15094603
[TBL] [Abstract][Full Text] [Related]
34. Global search for chromosomal abnormalities in infiltrating ductal carcinoma of the breast using array-comparative genomic hybridization.
Somiari SB; Shriver CD; He J; Parikh K; Jordan R; Hooke J; Hu H; Deyarmin B; Lubert S; Malicki L; Heckman C; Somiari RI
Cancer Genet Cytogenet; 2004 Dec; 155(2):108-18. PubMed ID: 15571796
[TBL] [Abstract][Full Text] [Related]
35. Chromogenic in situ hybridization: a multicenter study comparing silver in situ hybridization with FISH.
Bartlett JM; Campbell FM; Ibrahim M; Wencyk P; Ellis I; Kay E; Connolly Y; O'Grady A; Di Palma S; Starczynski J; Morgan JM; Jasani B; Miller K
Am J Clin Pathol; 2009 Oct; 132(4):514-20. PubMed ID: 19762528
[TBL] [Abstract][Full Text] [Related]
36. Intratumoral heterogeneity of her-2/neu in invasive mammary carcinomas using fluorescence in-situ hybridization and tissue microarray.
Shin SJ; Hyjek E; Early E; Knowles DM
Int J Surg Pathol; 2006 Oct; 14(4):279-84. PubMed ID: 17041191
[TBL] [Abstract][Full Text] [Related]
37. HER2 status in breast cancer determined by IHC and FISH: comparison of the results.
Mrozkowiak A; Olszewski WP; Piaścik A; Olszewski WT
Pol J Pathol; 2004; 55(4):165-71. PubMed ID: 15757204
[TBL] [Abstract][Full Text] [Related]
38. Determination of Her-2/Neu status in breast carcinoma: comparative analysis of immunohistochemistry and fluorescent in situ hybridization.
Jimenez RE; Wallis T; Tabasczka P; Visscher DW
Mod Pathol; 2000 Jan; 13(1):37-45. PubMed ID: 10658908
[TBL] [Abstract][Full Text] [Related]
39. [Determination of HER2 by fluorescence in situ hybridization (FISH) in breast cancer. Experience of the Reference Laboratory of Lisbon].
André S; Tomás AR; Fonseca R
Acta Med Port; 2005; 18(6):417-22. PubMed ID: 16684481
[TBL] [Abstract][Full Text] [Related]
40. Expression and amplification of Her2, EGFR and cyclin D1 in breast cancer: immunohistochemistry and chromogenic in situ hybridization.
Cho EY; Choi YL; Han JJ; Kim KM; Oh YL
Pathol Int; 2008 Jan; 58(1):17-25. PubMed ID: 18067636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
